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Abstract
Background: Counts of malaria parasites in peripheral blood are important to assess severity of Plasmodium
falciparum malaria. Thin and thick smears are routinely used for this purpose.
Methods: In this study the Binax NOW® Malaria Test, an easy-to-perform rapid diagnostic test, with Histidine Rich
Protein-2 (HRP-2) and aldolase as diagnostic markers, was used for semi-quantitative assessment of parasitaemia of
P. faciparum.
Results: In 257 patients with imported P. falciparum malaria, reactivity of aldolase increased with higher
parasitaemia. In all patients with a parasitaemia above 50,000 asexual parasites/μl (> 1%) co-reactivity of HRP-2 and
aldolase was observed. Absence of aldolase reactivity in the presence of HRP-2 was a reliable predictive marker to
exclude high (> 1%) parasitaemia in P. falciparum malaria.
Conclusions: Assessment of HRP-2 and aldolase co-reactivity can be of help in clinical decision making in the
acute care setting of returning travellers suspected of having malaria.
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Background
The global burden of malaria is largely carried by the
world’s malaria-endemic regions with as many as 225
million cases and a death toll of more than 750,000
individuals in 2009 [1]. In striking contrast, in non-
endemic industrialized countries malaria is seen as an
occasionally imported disease in non-immune travellers,
but it still represents a potentially fatal disease [2,3].
Without prompt and proper treatment malaria may
rapidly progress to complications and even death.
Hence, all patients must be assessed for signs or symp-
toms suggestive of an increased risk for complications.
Due to unfamiliarity with the disease in non-endemic
countries, ill-returning travellers frequently present to
physicians who have no tropical medicine expertise and
to primary health care facilities that lack expert
diagnostic capabilities. As a result, diagnosis of malaria
may be delayed or even missed, resulting in more severe
disease or even fatalities [4,5].
Recent studies in non-endemic industrialized countries
showed that rapid diagnostic tests (RDTs) for malaria pro-
vide an excellent tool for diagnosis of malaria as compared
to peripheral blood smears [6]. Although highly sensitive in
diagnosing Plasmodium falciparum malaria, RDTs are not
thought to provide sufficient information about parasitae-
mia, one of the major determinants of disease severity [1].
In the present multi-centre operational laboratory study it
is shown that the FDA approved three-band immunochro-
mographic RDT Binax NOW® Malaria Test allows a semi-
quantitative assessment of parasitaemia and rapid exclusion
of high P. falciparum parasitaemia, which may facilitate
clinical decision making in the acute care setting.
Methods
In order to assess the utility of this RDT as a semi-
quantitative measure of P. falciparum load in routine
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clinical practice, an operational laboratory study was
conducted at two hospital-based laboratories with exper-
tise in malaria diagnosis in The Netherlands (Academic
Medical Center, Amsterdam, The Netherlands; Harbour
Hospital, Rotterdam, The Netherlands). Of all patients
detailed demographic, clinical and laboratory data were
available, as well as the outcome measures severe
malaria and death. Severe malaria was diagnosed
according to predefined WHO criteria in travellers [7].
In both Dutch centres, parasitaemia was examined using
the same protocol. Thick and thin smears were stained
with Giemsa (Giemsa improved R66 Gurr, BDH, diluted
1:10, PH 7,2, 30 min). For an initial estimate of the
parasite load, malaria thin smears were examined by
light microscopy (100× objective and 12,5 ocular lens).
If the parasitaemia was assumed to be ≤0.5% infected
red blood cells, the exact parasite load was determined
by counting the number of asexual parasites per 100
leukocytes in a thick smear. In case the initial parasitae-
mia was assumed to be 0.5-2.0%, the number of infected
red blood cells was counted in 10 visual fields of a thin
smear. The number of red cells per microscopic field in
a thin smear was pre-calculated for the different micro-
scopes in use. In case the initial parasitaemia was
assumed to be >2.0%, the number of infected red blood
cells was determined using a special ocular lens with a
visual field area reduced to approximately 25%. Within
this limited field of view both the total number of red
blood cells and the number of infected red blood cells
were counted in at least 10 visual fields. All counts were
performed in duplicate and the final count was given as
the average. In case of a discrepancy of >15% between
the duplicate counts, a third count was performed. The
number of asexual parasites/μl was finally calculated
using the actual number of erythrocytes or leukocytes in
a blood sample.
The RDTs were performed on fresh blood samples,
simultaneously with microscopy of the blood slides.
Every RDT and blood slide was read by two indepen-
dent, experienced laboratory technicians. The Binax
NOW® Malaria Test was used as RDT and performed
according to the manufacturer’s instructions. The Binax
NOW® Malaria Test uses monoclonal antibodies that
target the histidine-rich protein 2 (HRP-2) antigen spe-
cific to P. falciparum (the ‘T1’ line) and the pan-malarial
antigen aldolase (the ‘T2’ line), common to all five Plas-
modium species that can be detected in humans (P. fal-
ciparum, Plasmodium vivax, Plasmodium ovale,
Plasmodium malariae and Plasmodium knowlesi) [8].
Aldolase co-reactivity was defined as both a reactive
HRP-2 line (T1 line) as well as a reactive aldolase line
(T2 line). Absence of aldolase co-reactivity was defined
as a non-reactive aldolase (T2) but a reactive HRP-2
(T1) line (Figure 1).
For external validation of the reproducibility of the
RDT findings in the Dutch centers, a reference center
for malaria diagnosis participated (Institute of Tropical
Medicine (ITM), Antwerp, Belgium). In this setting in
thick and thin blood films, stained with Giemsa (Merck
1.09204.0500, diluted to 3.5% in pH 8.0, 20 min.), para-
site densities were determined by counting asexual para-
sites against 200 white blood cells (WBC) in thick blood
films and converting this number to parasites/μl using
the actual white blood cell count [9]. Parasite densities
were next converted to % infected red blood cells using
the red blood cell count. For the purpose of this study,
ITM provided RDT findings in relation to the parasite
loads of 73 consecutive patients, but did not contribute
to the clinical data.
Results
A total of 257 patients with P. falciparum malaria were
included. All patients had HRP-2 reactivity in the Binax
NOW® Malaria Test. The general characteristics and
laboratory findings of 184 evaluable patients from
Amsterdam (Academic Medical Center) and Rotterdam
(Harbour Hospital) are provided in Table 1. The 23
patients with severe malaria presented with impaired
consciousness in seven (three of them had a Glasgow
Coma Score score < 11), severe anaemia in two, hyper-
bilirubinaemia in 12 and renal failure in three cases. Ele-
ven patients had a parasitaemia > 5% (4 of them had a
parasitaemia > 10%). Five patients received haemodialy-
sis and one patient died. Of the 73 Belgian patients no
clinical data were available.
Co-reactivity of HRP-2 and aldolase was observed in
blood specimens with both low and high parasitaemia,
ranging from 56 to 558,000 (Amsterdam), 23 to
1,380,600 (Rotterdam) and 26 to 400,000 asexual para-
sites/μl (Antwerp), respectively. The proportion of aldo-
lase co-reactivity substantially increased with increasing
parasitaemia (Figure 2). Aldolase co-reactivity was always
present when parasitaemia was above 50,000 asexual
parasites/μl (corresponding to approximately 1% parasi-
tized erythrocytes). This observation was valid not only
in the centers in Rotterdam and Amsterdam, but also in
the laboratory setting of Antwerp. All patients with
severe malaria (n = 23) invariably showed HRP-2 and
aldolase co-reactivity. Hence, aldolase co-reactivity with
HRP-2 had a sensitivity of 100% (95% confidence interval
85-100%) for severe malaria, but a poor positive predic-
tive value (PPV) of only 21% (95% CI 11-25%), since aldo-
lase co-reactivity was also present in 109 patients with
uncomplicated malaria. In contrast, absence of aldolase
reactivity (n = 52) had a negative predictive value (NPV)
of 100% (95% CI 93 - 100%) for severe malaria. The
implications of the RDT test outcomes for clinical deci-
sion-making are shown in Figure 1.
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Discussion
The results of the present study indicate that the Binax
NOW® Malaria Test allows a semi-quantitative assess-
ment of parasitaemia in travellers returning with P. fal-
ciparum malaria.
HRP-2 reactivity (T1) in absence of aldolase reactivity,
proved a reliable predictive marker for a low (< 1%) P.
falciparum parasitaemia. In the current study population
HRP-2 reactivity without aldolase reactivity was applic-
able to 30% of returning travellers with P. falciparum.
When clinical findings and routine laboratory results in
these patients also are not indicative of severe disease,
the patient most likely has uncomplicated malaria. This
knowledge is important for further clinical decision-
making.
Co-reactivity of aldolase and HRP-2 was present in all
patients with a parasitaemia above 50,000 asexual para-
sites/μl (corresponding to approximately 1% infected red
blood cells). Others reported co-reactivity with Binax
NOW® in 80% of patients with P. falciparum parasitae-
mia > 40,000 parasites/μl [9]. The authors suggested co-
reactivity of HRP-2 and aldolase possibly could function
as a semi-quantitative marker of high P. falciparum
parasitaemia [10]. In the present study this relation
proved, however, not straightforward with co-reactivity
of HRP-2 and aldolase also being present in patients
with low parasitaemia (i.e. < 0.5%). As such co-reactivity
of HRP-2 and aldolase is less reliable as marker for high
parasitaemia.
The data of the present study suggest that aldolase
and HRP-2 co-reactivity is present in all patients with
severe malaria. Apparently HRP-2 and aldolase reactiv-
ity, which depends on the load of these antigens in the
blood specimen, is preserved because these antigens are
derived not only from circulating viable and non-viable
malaria parasites, but also from sequestered parasites
that are abundantly present in severe malaria. As a con-
sequence of this sequestration, microscopic determina-
tion of peripheral blood smears might underestimate the
total parasitaemia.
The relation between aldolase reactivity and P. falci-
parum parasitaemia, as observed with Binax NOW® in
this study, could be dependent of the process of manu-
facturing. Other RDTs with a similar three-band config-
uration, therefore, should be studied in detail, to assess
about the precise relationship between P. falciparum
parasitaemia and aldolase reactivity.
HRP-2 and aldolase co-reactivity may also be a feature
of a mixed Plasmodium infection. In a recent study of
2,847 cases of imported malaria in the Netherlands [11],
Figure 1 Interpretation of the Binax NOW® Malaria test results in patients with P. falciparum infection, related to microscopic
parasitaemia.
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75% of the infections were solely caused by P. falci-
parum whereas the remainder was caused by P. vivax
(15%), P. ovale (7%), and P. malariae (3%), respectively.
Only 0,7% of all infections was attributable to mixtures
of species, mostly involving P. falciparum. Thus, in the
Dutch setting, HRP-2 and aldolase co-reactivity is far
more likely to reflect a mono-parasitic P. falciparum
infection rather than a mixed infection.
Results of RDT’s may facilitate clinical decision mak-
ing in patients suspected of having malaria. There are
however also some drawbacks to consider. First, these
tests cannot replace clinical assessment of the ill-return-
ing patient and results of RDT tests should always be
confirmed by thin or thick blood smears, including
parasite counts in case of P. falciparum malaria [6,12].
Second, the diagnostic power of this RDT test is depen-
dent on the epidemiological setting, in particular the
prevalence of the disease. The current findings may not
simply be extrapolated to regions of malaria endemicity
where low-grade malaria infections are far more preva-
lent and empirical anti-malarial treatment is common
use, which may lead to false-negative and false-positive
RDT findings, respectively. In addition, the majority of
the travellers in this study contracted P. falciparum
infection in Africa; other malaria-endemic continents
like South-East Asia and South-America were underre-
presented. Caution is warranted with extrapolating the
applicability of the current findings to imported malaria
acquired outside Africa. False negative results have been
suggested for certain genetic polymorphisms of HRP-2
geographically confined to the Asia-Pacific region [13]
Table 1 General characteristics and laboratory findings at initial clinical assessment of 184 patients with P. falciparum malaria
Parameter Amsterdam (AMC) Rotterdam (HZH)
Number of patients, n 77 107
Male/female 52/25 78/29
Age, median (range,) yrs 37 (0 - 61) 40 (16 - 70)
Purpose of travel
Immigrant, n (%) 4 (5.2) 0 (0.0)
Visiting friends and relatives, n (%) 48 (62.3) 36 (33.6)
Tourist, n (%) 6 (7.8) 20 (18.7)
Business, n (%) 10(13.0) 27 (25.2)
Expatriate, n (%) 0 (0.0) 4 (3.7)
Sailor, n (%) 0 (0.0) 4 (3.7)
Unknown, n (%) 9 (11.7) 11 (10.3)
Continent of acquisition
Africa, n (%) [West-Africa, n (%)] 73 (94.8) [63 (81.8)] 101 (94.9) [71 (66.4)]
South-America, n (%) 2 (2.6) 1 (0.9)
South East Asia, n (%) 2 (2.6) 7 (6.5)
Clinical assessment
Severe malaria, n (%) 7 (9.1) 16 (15.0)
Non-severe malaria, n (%) 70 (90.9) 91 (85.0)
Laboratory findings
Parasite load, median range, trophozoites/μL 4648 (50 - 558000) 10664 (2 - 1380600)
Malaria Now 77 (100) 107 (100)
HRP-2 and aldolase co-reactivity, n (%) 54 (70.1) 78 (72.9)
HRP-2 reactivity, n (%) 23 (29.9) 29 (27.1)
Figure 2 Co-reactivity of aldolase and HRP-2 bands in Binax
NOW® Malaria rapid diagnostic test in relation to P. falciparum
parasitaemia. Aldolase co-reactivity was consistently present at a
parasitaemia above 50,000 asexual parasites/μl, but variably
present at lower parasitaemia indicating that absence of aldolase
co-reactivity always was associated with a parasitaemia ≤ asexual
50,000 parasites/μl. The RDT findings (absence or presence of
aldolase co-reactivity) of the participating three centres are
shown in relation to category of parasitaemia and expressed as
mean ± SD. The number of patients per category of parasitaemia is
given within each respective bar.
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and for P. falciparum isolates from South America lack-
ing HRP-2 [14]. In addition, false negative test results
may occur at high parasitaemia due to a so-called pro-
zone effect, defined as false-negative or false-low results
in immunological reactions due to an excess of either
antigens or antibodies. The prozone effect was observed
for HRP-2 in 16 of 17 RDTs (including the Binax
NOW® Malaria Test), resulting in a false low HRP-2
signal, whereas aldolase reactivity was not affected [15].
Finally, the clinician must also consider the possibility of
a P. knowlesi infection, which may give rise to severe
disease and fatal complications as well [8]. Even though
early reports suggested that RDTs may not detect P.
knowlesi infections, later studies demonstrated that P.
knowlesi was reactive with the aldolase band in the
Binax NOW® Malaria Test, but not with HRP-2 and
that aldolase reactivity depended on the P. knowlesi
parasitaemia [8].
Conclusion
In conclusion, the RDT Binax NOW® Malaria Test
allows a rapid semi-quantitative assessment of P. falci-
parum load in travellers with malaria returning from the
tropics, especially for exclusion of high (>1%) parasitae-
mia in the acute care setting. This may facilitate clinical
decision making for subsequent oral anti-malarial treat-
ment or timely referral to a specialized centre for high-
level monitoring and intensified parenteral treatment.
Acknowledgements and Funding
Carla Wassenaar and Leny Nieuwendijk at the AMC, Amsterdam, Henk
Hofwegen and Yvonne Kuhn at the Harbour Hospital, Rotterdam, and Jessica
Maltha at the ITG, Antwerp, are acknowledged for technical assistance
during the study. All authors were funded by their respective institutes.
Author details
1Department of Parasitology, Academic Medical Center, Amsterdam, The
Netherlands. 2Department of Internal Medicine, Harbour Hospital, Rotterdam,
The Netherlands. 3Department of Parasitology, Harbour Hospital, Rotterdam,
The Netherlands. 4Department of Internal Medicine, Academic Medical
Center, Amsterdam, The Netherlands. 5Department of Clinical Sciences,
Institute of Tropical Medicine, Antwerp, Belgium. 6Department of Medical
Microbiology and Infectious Diseases, Erasmus University Hospital,
Rotterdam, The Netherlands. 7Institute for Tropical Diseases, Harbour
Hospital, Rotterdam, The Netherlands.
Authors’ contributions
TvG and PvG designed the study, acquired, analysed and interpreted data,
drafted and revised the manuscript, MvW acquired and analysed data, and
revised the manuscript, RK, PvT, JJ and JvH acquired, analysed and
interpreted data, and revised the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2011 Accepted: 14 October 2011
Published: 14 October 2011
References
1. World Health Organization: World Malaria Report 2010 [http://www.who.int/
malaria/publications], Accessed 25 January 2011..
2. Bruneel F, Tubach F, Corne P, Megarbane B, Mira JP, Peytel E, Camus C,
Schortgen F, Azoulay E, Cohen Y, Georges H, Meybeck A, Hyvernat H,
Trouillet JL, Frenoy E, Nicolet L, Roy C, Durand R, Le Bras J, Wolff M: Severe
imported falciparum malaria: a cohort study in 400 critically ill adults.
PloS One 2010, 5:e13236.
3. van Genderen PJ, Hesselink DA, Bezemer JM, Wismans PJ, Overbosch D:
Efficacy and safety of exchange transfusion as an adjunct therapy for
severe Plasmodium falciparum malaria in nonimmune travelers: a 10-
year single-center experience with a standardized treatment protocol.
Transfusion 2010, 50:787-794.
4. Kain KC, Harrington MA, Tennyson S, Keystone JS: Imported malaria:
prospective analysis of problems in diagnosis and management. Clin
Infect Dis 1998, 27:142-149.
5. Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T,
Kendjo E, Houze S, Le Bras J, Danis M, Durand R: Severe imported
Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis 2011,
17:807-13.
6. Stauffer WM, Cartwright CP, Olson DA, Juni BA, Taylor CM, Bowers SH,
Hanson KL, Rosenblatt JE, Boulware DR: Diagnostic performance of rapid
diagnostic tests versus blood smears for malaria in US Clinical practice.
Clin Infect Dis 2009, 49:908-13.
7. van Genderen PJ, van der Meer IM, Consten J, Petit PL, van Gool T,
Overbosch D: Evaluation of plasma lactate as a parameter for disease
severity on admission in travelers with Plasmodium falciparum malaria. J
Travel Med 2005, 12:261-264.
8. van Hellemond JJ, Rutten M, Koelewijn R, Zeeman AM, Verweij JJ,
Wismans PJ, Kocken CH, van Genderen PJ: Human Plasmodium knowlesi
infection detected by rapid diagnostic tests for malaria. Emerg Infect Dis
2009, 15:1478-1480.
9. Van der Palen M, Gillet P, Bottieau E, Cnops L, Van Esbroeck M, Jacobs J:
Test characteristics of two rapid antigen detection tests (SD FK50 and
SD FK60) for the diagnosis of malaria in returned travellers. Malar J 2009,
8:90.
10. Richter J, Gobels K, Muller-Stover I, Hoppenheit B, Haussinger D: Co-
reactivity of plasmodial histidine-rich protein 2 and aldolase on a
combined immuno-chromographic-malaria dipstick (ICT) as a potential
semi-quantitative marker of high Plasmodium falciparum parasitaemia.
Parasitol Res 2004, 94:384-385.
11. van Rijckevorsel GG, Sonder GJ, Geskus RB, Wetsteyn JC, Ligthelm RJ,
Visser LG, Keuter M, van Genderen PJ, van den Hoek A: Declining
incidence of imported malaria in the Netherlands, 2000-2007. Malar J
2010, 9:300.
12. Durand F, Crassous B, Fricker-Hidalgo H, Carpentier F, Brion JP, Grillot R,
Pelloux H: Performance of the Now Malaria rapid diagnostic test with
returned travellers: a 2-year retrospective study in a French teaching
hospital. Clin Microbiol Infect 2005, 11:903-907.
13. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, Bell D,
Cheng Q: Genetic diversity of Plasmodium falciparum histidine-rich
protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based
rapid diagnostic tests. J Infect Dis 2005, 192:870-877.
14. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW,
Incardona S, Perkins M, Bell D, McCarthy J, Cheng Q: A large proportion of
P. falciparum isolates in the Amazon Region of Peru Lack pfhrp2 and
pfhrp3: implications for malaria rapid diagnostic tests. PLoS ONE 2010, 5:
e8091.
15. Gillet P, Mori M, van Esbroeck M, van den Ende J, Jacobs J: Assessment of
the prozone effect in malaria rapid diagnostic tests. Malar J 2009, 8:271.
doi:10.1186/1475-2875-10-300
Cite this article as: van Gool et al.: A simple and fast method to exclude
high Plasmodium falciparum parasitaemia in travellers with imported
malaria. Malaria Journal 2011 10:300.
van Gool et al. Malaria Journal 2011, 10:300
http://www.malariajournal.com/content/10/1/300
Page 5 of 5
